Genetic susceptibility to aminoglycoside cochleotoxicity in South African multidrug-resistant and rifampicin-resistant tuberculosis patients
South African Journal of Communication Disorders · 2026
DOI: 10.4102/sajcd.v73i1.1180 ↗Kurz gefasst
Fachartikel in der Zeitschrift South African Journal of Communication Disorders, 2026. Verfasst von Nazanin Ghafari und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health and Rehabilitation Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town. nazanin.ghafari@uct.ac.za. Hauptthemen laut MEDLINE: Tuberculosis, Multidrug-Resistant, Ototoxicity, Kanamycin, Aminoglycosides. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Background
South Africa has a high burden of multidrug-resistant tuberculosis (MDR-TB) and rifampicin-resistant tuberculosis (RR-TB). At the time of this study, kanamycin formed part of the South African MDR/RR-TB treatment regimen. Although treatment has shifted towards shorter all-oral regimens, aminoglycoside-related ototoxicity remains clinically relevant.
Objectives
This study investigated the association between two mitochondrial variants, m.15312T>C (I189T in MT-CYB [mitochondrially encoded cytochrome b]) and m.10114T>C (I19T in MT-ND3 [mitochondrially encoded NADH]), and susceptibility to cochleotoxicity in South African patients receiving kanamycin-based MDR/RR-TB treatment.
Method
A prospective cohort study was conducted in Cape Town, South Africa. Hearing thresholds from 0.25 kHz to 16 kHz were monitored at baseline and at 4 weeks, 8 weeks and 12 weeks after treatment initiation. Cochleotoxicity was defined using the American Speech-Language-Hearing Association’s significant threshold shift criteria. Mitochondrial variants were identified using polymerase chain reaction and Sanger sequencing. Fisher’s exact tests were used to explore associations between variants and cochleotoxicity.
Results
Hearing data were analysed for 102 participants. Cochleotoxicity developed in 84 participants (82.4%). The m.15312T>C variant was detected in three of 78 successfully sequenced participants, and m.10114T>C in four of 80. All variant carriers had cochleotoxicity. Statistically significant associations were not demonstrated for m.15312T>C (p = 1.000) or m.10114T>C (p = 1.000).
Conclusion
The variants were observed only among participants who developed cochleotoxicity, but no statistically significant associations were observed. The findings are exploratory and require validation before clinical screening. Contribution: This study supports future genetic-susceptibility research in African aminoglycoside-exposed populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health and Rehabilitation Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town. nazanin.ghafari@uct.ac.za.
Förderung
- NIAID NIH HHS
Zitieren
APA
Ghafari, N., Ramma, L., Court, R., Manyisa, N., McIlleron, H., & Petersen, L. (2026). Genetic susceptibility to aminoglycoside cochleotoxicity in South African multidrug-resistant and rifampicin-resistant tuberculosis patients. South African Journal of Communication Disorders. https://doi.org/10.4102/sajcd.v73i1.1180
Vancouver
Ghafari N, Ramma L, Court R, Manyisa N, McIlleron H, Petersen L. Genetic susceptibility to aminoglycoside cochleotoxicity in South African multidrug-resistant and rifampicin-resistant tuberculosis patients. South African Journal of Communication Disorders. 2026. doi:10.4102/sajcd.v73i1.1180
BibTeX
@article{Ghafari2026,
author = {Ghafari, Nazanin and Ramma, Lebogang and Court, Richard and Manyisa, Noluthando and McIlleron, Helen and Petersen, Lucretia},
title = {Genetic susceptibility to aminoglycoside cochleotoxicity in South African multidrug-resistant and rifampicin-resistant tuberculosis patients},
journal = {South African Journal of Communication Disorders},
year = {2026},
doi = {10.4102/sajcd.v73i1.1180}
}
EUVIMED